Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Helperby Therapeutics
Helperby Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
How can we save medicine from superbug disaster?
Two leading research teams to collaborate on new fast track antibiotic therapies, with an aim to bring new sophisticated combination therapies to market in a much-reduced timescale
Ingredients
Two of the world’s leading research teams to collaborate on new fast track antibiotic therapies
Aiming to bring new sophisticated combination therapies to market in a much reduced timescale
Regulatory
Treatments to solve global antibiotic crisis may reach the market in 2020
Helperby Therapeutics has developed the first sustainable solution to combat all three deadly critical priority pathogens named by World Health Organisation (WHO)<sup>1</sup>
Research & Development
Helperby Therapeutics and Cadila sign antibiotic drug resistance agreement
Cadila will take a new Helperby compound through Phase III trials, approvals and into commercialisation
Subscribe now